Skip to main content
SpringerLink
Log in

Ibrutinib-Kombination schlägt CLL-Standardtherapie

  • Hämatologie
  • Literatur kompakt
  • Published:
Im Fokus Onkologie Aims and scope

Die Erstbehandlung mit Ibrutinib plus Rituximab verlängert bei jüngeren CLL-Patienten im Vergleich zu einer Chemoimmuntherapie das progressionsfreie sowie das Gesamtüberleben. Darauf deutet die Interimsanalyse einer Phase-III-Studie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Shanafelt TD et al. Ibrutinib—Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 2019; 381(5):432–43

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Thomas Müller

Authors
  1. Thomas Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Müller, T. Ibrutinib-Kombination schlägt CLL-Standardtherapie. Im Fokus Onkologie 22, 24–25 (2019). https://doi.org/10.1007/s15015-019-0735-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-019-0735-9

Search

Navigation